A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Patients With Active Ankylosing Spondylitis

Trial Profile

A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Patients With Active Ankylosing Spondylitis

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 20 Oct 2015

At a glance

  • Drugs Ixekizumab (Primary) ; Adalimumab
  • Indications Ankylosing spondylitis
  • Focus Registrational; Therapeutic Use
  • Acronyms SPIRIT-A1
  • Sponsors Eli Lilly
  • Most Recent Events

    • 21 Jan 2014 Status changed from recruiting to withdrawn prior to recruitment according to ClinicalTrials.gov record.
    • 05 Oct 2013 Ne source identified and integrated (European Clinical Trials Database: EudraCT2011-002325-22).
    • 26 Sep 2013 Status changed from not yet recruiting to recruiting as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top